Rifamycin PR-3
Product Code: AG-CN2-0335
Product Group: Natural Products and Extracts
Supplier: AdipoGen Life Sciences
| Code | Size | Price |
|---|
| AG-CN2-0335-M010 | 10 mg | £100.00 |
Quantity:
| AG-CN2-0335-M050 | 50 mg | £370.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
AMBIENT
Storage:
-20°C
Documents
Further Information
Alternate Names/Synonyms:
3'-(Methoxycarbonyl)-1',2'-dimethyl-rifamycin II; NCI 143-458; NCI 143458
Appearance:
Yellow to orange powder.
CAS:
21288-98-2
EClass:
32160000
Form (Short):
liquid
Handling Advice:
Keep cool and dry.Protect from light.Protect from light when in solution.
InChi:
InChI=1S/C43H54N2O13/c1-18-14-13-15-19(2)41(52)44-32-29-27(42(53)55-12)24(7)45(10)33(29)28-30(37(32)50)36(49)23(6)39-31(28)40(51)43(9,58-39)56-17-16-26(54-11)20(3)38(57-25(8)46)22(5)35(48)21(4)34(18)47/h13-18,20-22,26,34-35,38,47-50H,1-12H3,(H,44,52)/b14-13+,17-16+,19-15-/t18-,20+,21+,22+,26?,34-,35+,38+,43-/m0/s1
InChiKey:
ZFTSGTXASLVDRX-STQZBDMOSA-N
Long Description:
Chemical. CAS: 21288-98-2. Formula: C43H54N2O13. MW: 806.9. Semisynthetic. Ansamycin antibiotic. Selective inhibitor of bacterial DNA-dependent RNA polymerase (RNAP). Effective against mycobacteria, and are therefore used in research of tuberculosis, leprosy and mycobacterium avium complex (MAC) infections.
Molecular Formula:
C43H54N2O13
Molecular Weight:
806.9
Package Type:
Vial
Product Description:
Ansamycin antibiotic. Selective inhibitor of bacterial DNA-dependent RNA polymerase (RNAP). Effective against mycobacteria and therefore used in research of tuberculosis, leprosy and Mycobacterium avium complex (MAC) infections.
Purity:
>94% (HPLC)
SMILES:
OC1=C(NC(/C(C)=CC=C[C@H](C)[C@H](O)[C@@H](C)[C@H]([C@@H](C)[C@@H]([C@H](C)[C@H](/C=C/O2)OC)OC(C)=O)O)=O)C3=C(N(C)C(C)=C3C(OC)=O)C4=C5C(O[C@@]2(C)C5=O)=C(C)C(O)=C41
Solubility Chemicals:
Soluble in DMSO, aqueous acetonitrile or ethanol.
Source / Host:
Semisynthetic.
Transportation:
Non-hazardous
UNSPSC Category:
Natural Products/Extracts
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.
References
Rifamycin antibiotics: inhibitors of Rauscher murine leukemia virus reverse transcriptase and of purified DNA polymerases from human normal and leukemic lymphoblasts: S.S. Yang, et al.; J. Natl. Cancer Inst. 49, 7 (1972) | Rifamycin Derivatives Strongly Inhibiting RNA>DNA Polymerase (Reverse Transcriptase) of Murine Sarcoma Viruses: C. Gurgo, et al.; J. Natl. Cancer Inst. 49, 61 (1972) | Reverse transcriptase, RNA tumour virus transformation and derivatives of rifamycin SV: R.C. Ting, et al.; Nat. New Biol. 236, 163 (1972) | Interaction between murine type-C virus RNA-directed DNA polymerases and rifamycin derivatives: A.M. Wu & R.C. Gallo; Biochim. Biophys. Acta 340, 419 (1974)
Related Products
| Product Name | Product Code | Supplier | Rifamycin AF | AG-CN2-0321 | AdipoGen Life Sciences | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rifamycin AF-API | AG-CN2-0325 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Rifamycin AF-EPTAPI | AG-CN2-0326 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Rifamycin AF-DA | AG-CN2-0328 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Rifamycin AG | AG-CN2-0329 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Rifamycin AMI-DA | AG-CN2-0330 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Rifamycin AMP-DA | AG-CN2-0331 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Rifamycin M14 | AG-CN2-0332 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Rifamycin O | AG-CN2-0333 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Rifamycin PR-14 | AG-CN2-0334 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||